Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate…
